The PE Ratio as of November 2024 (TTM) for Ono Pharmaceutical Co., Ltd. (OPHLY) is 8.70

According to Ono Pharmaceutical Co., Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is 8.70. This represents a change of -5.20% compared to the average of 9.18 of the last 4 quarters.

Ono Pharmaceutical Co., Ltd. (OPHLY) Historical PE Ratio (quarterly & annually)

How has OPHLY PE Ratio performed in the past?

The mean historical PE Ratio of Ono Pharmaceutical Co., Ltd. over the last ten years is 36.30. The current 8.70 PE Ratio has changed 2.30% with respect to the historical average. Over the past ten years (40 quarters), OPHLY's PE Ratio was at its highest in in the September 2014 quarter at 668.09. The PE Ratio was at its lowest in in the March 2015 quarter at -129.04.

Ono Pharmaceutical Co., Ltd. (OPHLY) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Ono Pharmaceutical Co., Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Ono Pharmaceutical Co., Ltd. (OPHLY) Average PE Ratio

How has OPHLY PE Ratio performed in the past?

The current PE Ratio of Ono Pharmaceutical Co., Ltd. (OPHLY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Ono Pharmaceutical Co., Ltd. (OPHLY) PE Ratio vs. Peers

How is OPHLY’s PE Ratio compared to its peers?

Ono Pharmaceutical Co., Ltd.’s PE Ratio is less than Santen Pharmaceutical Co., Ltd. (21.08), less than GSK plc (21.56), less than Grifols, S.A. (31.16), less than Pfizer Inc. (34.12), greater than Sanofi (8.31), greater than Organon & Co. (3.02), less than Horizon Therapeutics Public Limited Company (51.10), less than GSK plc (22.01), less than AstraZeneca PLC (31.32), less than Roche Holding AG (15.77), less than Novartis AG (11.92), less than Merck & Co., Inc. (20.67), greater than Bristol-Myers Squibb Company (-16.45), less than Gilead Sciences, Inc. (892.59), less than Amgen Inc. (37.39), less than Johnson & Johnson (25.44), less than AbbVie Inc. (61.11),

Build a custom stock screener for Ono Pharmaceutical Co., Ltd. (OPHLY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ono Pharmaceutical Co., Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ono Pharmaceutical Co., Ltd. (OPHLY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ono Pharmaceutical Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.